ZYDUSLIFE1,118.50

Zydus Lifesciences Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMADRREDDYCIPLATORNTPHARMDIVISLABMAXHEALTHAPOLLOHOSPAUROPHARMAMcap ₹1.13L Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations19,547.423,241.527,148.428,591.7
Other Income284.1269.5509.5460.7
Total Income19,831.523,511.027,657.929,052.4
Expenses
+ Cost of Materials Consumed4,580.54,372.95,109.65,141.9
+ Purchases of Stock-in-Trade1,897.92,150.03,070.53,701.5
+ Changes in Inventories-250.2-184.9-887.5-1,100.5
+ Employee Benefit Expense3,137.63,680.64,417.94,780.9
+ Finance Costs81.2165.9438.9510.2
+ Depreciation & Amortisation764.1915.81,408.01,724.6
+ Other Expenses4,797.36,164.46,962.87,751.9
Total Expenses15,008.417,264.720,520.222,510.5
EBITDA5,384.37,058.58,475.18,316.0
EBIT4,620.26,142.77,067.16,591.4
Profit
PBT before Exceptional Items4,823.16,246.37,137.76,541.9
+ Exceptional Items-14.2-219.6-516.6-534.8
Pretax Income4,808.96,026.76,621.16,007.1
+ Current Tax1,492.62,049.31,379.51,524.7
+ Deferred Tax-515.1-637.4215.2-9.8
Tax Expense977.51,411.91,594.71,514.9
+ Share of Associates & JVs118.457.897.1100.5
Net Income3,972.84,672.65,123.54,592.7
+ Net Income — Continuing Ops3,831.44,614.85,026.44,492.2
+ Net Income — Discontinued Ops23.00.00.00.0
+ Other Comprehensive Income-200.1-100.0-774.8-812.2
Total Comprehensive Income3,772.74,572.64,348.73,780.5
Net Income to Common113.3147.15,040.04,513.0
Minority Interest3,859.54,525.583.579.7
Per Share
Basic EPS38.1444.9750.0944.87
Diluted EPS38.1444.9750.0944.87
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax29.20.00.00.0
+ Tax — Discontinued Operations6.20.00.00.0
Other Comprehensive Income — detail
+ Other Comprehensive Income-100.0-774.8-812.2
+ Items NOT to be Reclassified to P&L-54.3-0.5-32.9-3.5
+ Tax on Items NOT to be Reclassified0.013.516.0
+ Tax on Items NOT to be Reclassified — alt tag-6.1
+ Items to be Reclassified to P&L-151.9-99.5-728.4-792.7
Comprehensive Income — Owners of Parent3,659.4146.94,267.33,707.6
Comprehensive Income — Non-controlling Interests113.34,425.781.472.9
Per Share — as-filed variants
Basic EPS — Continuing Operations37.9144.9750.0944.87
Diluted EPS — Continuing Operations37.9144.9750.0944.87
Basic EPS — Discontinued Operations0.230.000.000.00
Diluted EPS — Discontinued Operations0.230.000.000.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit13,319.216,903.519,855.820,848.8
Gross Margin %68.1472.7373.1472.92
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)4,823.16,246.37,137.76,541.9
− Exceptional Items (reconciliation)-14.2-219.6-516.6-534.8
Net Income Adj (tax-effected)3,984.14,840.85,515.74,992.6
EPS Adj38.2546.5953.9248.78
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital100.6100.6100.699.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.